Mahalingam D - Search Results

1

Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.

Carew JS, Medina EC, Esquivel JA 2nd, Mahalingam D, Swords R, Kelly K, Zhang H, Huang P, Mita AC, Mita MM, Giles FJ, Nawrocki ST. Carew JS, et al. Among authors: mahalingam d. J Cell Mol Med. 2010 Oct;14(10):2448-59. doi: 10.1111/j.1582-4934.2009.00832.x. J Cell Mol Med. 2010. PMID: 19583815 Free PMC article.

2

Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC).

Mahalingam D, Chen S, Xie P, Loghmani H, Heineman T, Kalyan A, Kircher S, Helenowski IB, Mi X, Maurer V, Coffey M, Mulcahy M, Benson A, Zhang B. Mahalingam D, et al. Br J Cancer. 2023 Sep;129(5):782-790. doi: 10.1038/s41416-023-02344-5. Epub 2023 Jul 13. Br J Cancer. 2023. PMID: 37443348 Free PMC article.

3

Challenges in developing targeted therapy for pancreatic adenocarcinoma.

Mahalingam D, Giles F. Mahalingam D, et al. Expert Opin Ther Targets. 2008 Nov;12(11):1389-401. doi: 10.1517/14728222.12.11.1389. Expert Opin Ther Targets. 2008. PMID: 18851695 Review.

4

Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow.

Kelly K, Swords R, Kilcoyne A, Sankhala K, Mahalingam D, Padmanabhan S, Giles F. Kelly K, et al. Among authors: mahalingam d. Leuk Lymphoma. 2009 Feb;50(2):297-9. doi: 10.1080/10428190802607541. Leuk Lymphoma. 2009. PMID: 19160124 No abstract available.

5

Targeting the mTOR pathway using deforolimus in cancer therapy.

Mahalingam D, Sankhala K, Mita A, Giles FJ, Mita MM. Mahalingam D, et al. Future Oncol. 2009 Apr;5(3):291-303. doi: 10.2217/fon.09.9. Future Oncol. 2009. PMID: 19374536 Review.

6

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.

Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Kelly K, et al. Among authors: mahalingam d. Target Oncol. 2009 Apr;4(2):99-105. doi: 10.1007/s11523-009-0110-4. Epub 2009 Apr 21. Target Oncol. 2009. PMID: 19381453 Review.

7

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.

Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M. Sankhala K, et al. Among authors: mahalingam d. Target Oncol. 2009 Apr;4(2):135-42. doi: 10.1007/s11523-009-0107-z. Epub 2009 Apr 21. Target Oncol. 2009. PMID: 19381454 Review.

8

Targeting HSP90 for cancer therapy.

Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Mahalingam D, et al. Br J Cancer. 2009 May 19;100(10):1523-9. doi: 10.1038/sj.bjc.6605066. Epub 2009 Apr 28. Br J Cancer. 2009. PMID: 19401686 Free PMC article. Review.

9

Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development.

Mahalingam D, Mita A, Mita MM, Nawrocki ST, Giles FJ. Mahalingam D, et al. Curr Probl Cancer. 2009 Mar-Apr;33(2):73-111. doi: 10.1016/j.currproblcancer.2009.03.001. Curr Probl Cancer. 2009. PMID: 19409299 Review. No abstract available.

10

Emerging drugs in the treatment of pancreatic cancer.

Mahalingam D, Kelly KR, Swords RT, Carew J, Nawrocki ST, Giles FJ. Mahalingam D, et al. Expert Opin Emerg Drugs. 2009 Jun;14(2):311-28. doi: 10.1517/14728210902972502. Expert Opin Emerg Drugs. 2009. PMID: 19466902 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

118 results

Search Page

Filters